Inaphaea BioLabs: ValiRx tCRO®

Inaphaea BioLabs is a new pharmaceutical services company, based in Nottingham (UK), offering cell-based assays specialising in oncology and women's health. Our aim is to improve the translation of early drug discovery projects towards the clinic. Driven by a desire to generate a deeper biological understanding of drug candidates in the discovery and preclinical phases of development, Inaphaea will provide testing services that generate the necessary data, analysis and insights to aid decision-making in translational drug development.

Initial services will be focussing on cancer cell activity; allowing the study of drug candidates in a range of cell lines to consider the activity, toxicity and mechanism of test molecules.  Further techniques and technologies will be added to the portfolio, with new capabilities fully validated on our in-house projects before being offered to external users.

The Inaphaea BioLabs Team

Spun out from ValiRx in Q4 of 2023 as a wholly owned subsidiary, the core team within Inaphaea have a strong background in preclinical and clinical drug development, and in understanding both the commercial and scientific needs of the service users from both sides of the table.

Dr Andrew Carnegie has been appointed as Head of Strategic Commercial Development. With more than 17 years’ of business and commercial development experience in the biotech and life sciences sectors, Andrew will lead Inaphaea’s growth strategy and secure third-party business.

Melissa Barr joins Inaphaea as Lead Scientist, with Dr Dominic Lowen appointed as Senior Scientist, Amelia Hatfield as Scientist and Zai Ahmad, appointed as ValiRx Preclinical Project Manager.

Read our news release piece on the launch of Inaphaea BioLabs, where you can read about the newly appointed team here.

Contact us

Please visit www.inaphaea.com for further information and contact info@inaphaea.com to register your interest in discussing our services.